Molecule Information

General Information of the Molecule (ID: Mol04427)

Name	Collagen triple helix repeat-containing protein 1 (CTHRC1) ,Homo sapiens
Molecule Type	Protein
Gene Name	CTHRC1
Gene ID	115908
Sequence	MRPQGPAASPQRLRGLLLLLLLQLPAPSSASEIPKGKQKAQLRQREVVDLYNGMCLQGPA GVPGRDGSPGANGIPGTPGIPGRDGFKGEKGECLRESFEESWTPNYKQCSWSSLNYGID L GKIAECTFTKMRSNSALRVLFSGSLRLKCRNACCQRWYFTFNGAECSGPLPIEAIIYL DQ GSPEMNSTINIHRTSSVEGLCEGIGAGLVDVAIWVGTCSDYPKGDASTGWNSVSRII IEE LPK Click to Show/Hide
Function	May act as a negative regulator of collagen matrixdeposition. {ECO:0000250}. Click to Show/Hide
Uniprot ID	CTHR1_HUMAN
Ensembl ID	ENSG0000016493213
HGNC ID	HGNC:18831
*Click to Show/Hide the Complete Species Lineage*
Kingdom: Metazoa Phylum: Chordata Class: Mammalia Order: Primates Family: Hominidae Genus: Homo Species: Homo sapiens

Type(s) of Resistant Mechanism of This Molecule

ADTT: Aberration of the Drug's Therapeutic Target

Drug Resistance Data Categorized by Drug

Preclinical Drug(s)

1 drug(s) in total

Click to Show/Hide the Full List of Drugs

SB590885

Click to Show/Hide

Drug Resistance Data Categorized by Their Corresponding Mechanisms
Aberration of the Drug's Therapeutic Target (ADTT)		Click to Show/Hide
Disease Class: Colon cancer [ICD-11: 2B90.1]			[1]
Resistant Disease	Colon cancer [ICD-11: 2B90.1]		Disease Info
Resistant Drug	SB590885		Drug Info
Molecule Alteration	Mutations	Arg622Ile
Experiment for Molecule Alteration	qRT-PCR; Immune cells infiltrating assay
Experiment for Drug Resistance	Immunohistochemistry assay; Pearson correlation testing
Mechanism Description	Colon cancer, thyroid cancer, and melanoma are common malignant tumors that seriously threaten human health globally. The B-Raf proto-oncogene, serine/threonine kinase (BRAF)(V600E) mutation is an important driver gene mutation in these cancer types. In this study, we identified that collagen triple helix repeat containing 1 (CTHRC1) expression was associated with the BRAF(V600E) mutation in colon cancer, thyroid cancer, and melanoma. A high level of CTHRC1 was correlated with decreased sensitivity to antitumor drugs (vemurafenib, PLX-4720, dabrafenib, and SB-590885) targeting the BRAF(V600E) mutation.

References

Ref 1	CTHRC1 is associated with BRAF(V600E) mutation and correlates with prognosis, immune cell infiltration, and drug resistance in colon cancer, thyroid cancer, and melanoma. Biomol Biomed. 2024 Dec 11;25(1):42-61.